Gates Foundation to launch trial of long-awaited new tuberculosis vaccine candidate
The Gates Foundation said Wednesday it plans to launch a long-awaited trial to test what, if proven effective, would be the first new tuberculosis vaccine in over a century.
The 26,000-person, phase 3 study will test a vaccine known as M72/AS01 that showed promising results from a smaller trial in 2019. The findings stoked excitement at the time. But a larger, confirmatory study was delayed as GSK, the company then developing it, transferred the shot to the Gates Foundation rather than move forward with the vaccine itself.
